DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling
The Drug Enforcement Administration (DEA) has unveiled new production quotas for Schedule I and II controlled substances, with a notable emphasis on boosting the supply of certain psychedelics for research purposes. As Marijuana Moment reported, among the substances marked for increased production are psilocybin, psilocyn and ibogaine, reflecting growing scientific interest in their therapeutic potential. At the same time, marijuana production quotas have remained unchanged as the agency prepares for a pivotal decision regarding its rescheduling.
Increased Psychedelic Production To Support Research
In the revised 2024 and newly proposed 2025 quotas, the DEA is advocating for a significant increase in the manufacturing of psychedelics such as psilocybin and psilocyn. The 2024 quotas have been raised to 30,000 grams and 36,000 grams, respectively, with those levels continuing into 2025. Similarly, ibogaine production will jump from 150 grams to 210 grams in 2025 to accommodate rising demand for research.
“These proposed increases are to support …